43 results on '"Nicolaescu, Vlad"'
Search Results
2. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model
3. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
4. Physics-driven structural docking and protein language models accelerate antibody screening and design for broad-spectrum antiviral therapy
5. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant
6. Abstract 12853: Superiority of Intranasal Over Systemic Administration of a Soluble ACE2 Protein (ACE2 618-DDC-ABD) in SARS-CoV-2 Infected Mice
7. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
8. A Soluble ACE2 Protein Improves Survival and Lowers Viral Titers in a Lethal Mouse Model of SARS-CoV-2 Infection with the Delta Variant
9. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
10. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2
11. Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure
12. Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection
13. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity
14. Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection
15. SARS-CoV-2 Diverges from Other Betacoronaviruses in Only Partially Activating the IRE1α/XBP1 Endoplasmic Reticulum Stress Pathway in Human Lung-Derived Cells
16. A comprehensive SARS-CoV-2–human protein–protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets
17. A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
18. The cargo adaptor protein CLINT1 is phosphorylated by the Numb-associated kinase BIKE and mediates dengue virus infection
19. Spherical nucleic acids as an infectious disease vaccine platform
20. A comprehensive SARS-CoV-2-human protein-protein interactome network reveals novel pathobiology and host-targeting therapies for COVID-19
21. SARS-CoV-2 diverges from other betacoronaviruses in only partially activating the IRE1α/XBP1 ER stress pathway in human lung-derived cells
22. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
23. Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity
24. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant
25. Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity
26. Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
27. Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Infection as an Innate Antiviral Mechanism
28. Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Infection as an Innate Antiviral Mechanism
29. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro
30. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
31. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2
32. Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release
33. The Role of Structural Flexibility in Hydrocarbon‐Stapled Peptides Designed to Block Viral Infection via Human ACE2 Mimicry.
34. Polycomb a potential barrier to de-differentiation in somatic plant tissue
35. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.
36. Novel antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy.
37. Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection.
38. SARS-CoV-2 diverges from other betacoronaviruses in only partially activating the IRE1α/XBP1 ER stress pathway in human lung-derived cells.
39. A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.
40. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.
41. Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.
42. Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response.
43. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro .
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.